Merdad Parsey
CIK: 0001792150
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Jun 18, 2026AVBP
ArriVent BioPharma, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
13.6K shares- - Jun 16, 2026ARDX
ARDELYX, INC.
Award(A)Direct26.5K shares- - Jun 18, 2025ARDX
ARDELYX, INC.
Award(A)Direct15.2K shares- - Jun 18, 2025AVBP
ArriVent BioPharma, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
15.5K shares- - Apr 28, 2025ARDX
ARDELYX, INC.
Award(A)Direct42.1K shares- - Apr 28, 2025AVBP
ArriVent BioPharma, Inc.
Award(A)DirectStock Option (right to buy)
28.3K shares- - Dec 10, 2024GILD
GILEAD SCIENCES, INC.
Tax Payment(F)Direct1.8K shares at avg. $92.34$164K - Dec 10, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct3.8K shares- - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct57.3K shares at avg. $57.92$3.3M - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct57.3K shares at avg. $91.79$5.3M - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct88.1K shares at avg. $92.00$8.1M - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct5.2K shares at avg. $91.80$477K - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct3.2K shares at avg. $91.80$294K - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct10.4K shares at avg. $92.00$957K - Nov 27, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct88.1K shares at avg. $65.38$5.8M - Nov 6, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct20.6K shares at avg. $91.50$1.9M - Nov 6, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct5K shares at avg. $91.50$458K - Nov 6, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct25K shares at avg. $57.92$1.4M - Oct 1, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct2K shares at avg. $83.83$168K - Sep 12, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct25K shares at avg. $57.92$1.4M - Sep 12, 2024GILD
GILEAD SCIENCES, INC.
Sale(S)Direct21.2K shares at avg. $84.50$1.8M - Sep 10, 2024GILD
GILEAD SCIENCES, INC.
Exercise(M)Direct3.8K shares- - Sep 10, 2024GILD
GILEAD SCIENCES, INC.
Tax Payment(F)Direct1.8K shares at avg. $81.44$144K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AVBP ArriVent BioPharma, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 13,562 | - | - | Direct |
| Jun 16, 2026 |  ARDX ARDELYX, INC. | Award(A) | 26,455 | - | $0 | Direct |
| Jun 18, 2025 | ARDX ARDELYX, INC. | Award(A) | 15,235 | - | - | Direct |
| Jun 18, 2025 | AVBP ArriVent BioPharma, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 15,502 | - | - | Direct |
| Apr 28, 2025 | ARDX ARDELYX, INC. | Award(A) | 42,056 | - | - | Direct |
| Apr 28, 2025 | AVBP ArriVent BioPharma, Inc. | Award(A) Stock Option (right to buy) | 28,346 | - | - | Direct |
| Dec 10, 2024 |  GILD GILEAD SCIENCES, INC. | Tax Payment(F) | 1,771 | $92.34 | $163,534 | Direct |
| Dec 10, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 3,820 | - | $0 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 57,294 | $57.92 | $3,318,468 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 57,294 | $91.79 | $5,259,297 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 88,119 | $92.00 | $8,106,948 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 5,200 | $91.80 | $477,381 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 3,199 | $91.80 | $293,679 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 10,399 | $92.00 | $956,708 | Direct |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 88,119 | $65.38 | $5,761,220 | Direct |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 20,590 | $91.50 | $1,883,985 | Direct |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 5,000 | $91.50 | $457,500 | Direct |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 25,000 | $57.92 | $1,448,000 | Direct |
| Oct 1, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 2,000 | $83.83 | $167,660 | Direct |
| Sep 12, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 25,000 | $57.92 | $1,448,000 | Direct |
| Sep 12, 2024 | GILD GILEAD SCIENCES, INC. | Sale(S) | 21,246 | $84.50 | $1,795,287 | Direct |
| Sep 10, 2024 | GILD GILEAD SCIENCES, INC. | Exercise(M) | 3,821 | - | $0 | Direct |
| Sep 10, 2024 | GILD GILEAD SCIENCES, INC. | Tax Payment(F) | 1,766 | $81.44 | $143,823 | Direct |
1-23 of 23 transactions
About Parsey Merdad
Parsey Merdad (SEC CIK 0001792150) files insider reports with the SEC as Director of ArriVent BioPharma, Inc. (AVBP), Director of ARDELYX, INC. (ARDX) and Chief Medical Officer of GILEAD SCIENCES, INC. (GILD).
Signal8 holds 14 ownership filings by Parsey Merdad (2 Form 3, 12 Form 4), filed between Sep 11, 2024 and Jun 22, 2026. Those filings report 23 transactions, from Sep 10, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Parsey Merdad's filings is in WALTHAM, MA.
Recent filings by Parsey Merdad
- Jun 18, 2026: Grant or award of AVBP derivative securities (Form 4, code A).
- Jun 16, 2026: Grant or award of ARDX shares (Form 4, code A).
- Jun 18, 2025: Grant or award of ARDX shares (Form 4, code A).
- Jun 18, 2025: Grant or award of AVBP derivative securities (Form 4, code A).
- Apr 28, 2025: Grant or award of ARDX shares (Form 4, code A).
Other insiders filing for ArriVent BioPharma, Inc. (AVBP)
- LaChapelle Robin, Chief Operating Officer
- Peterson Kristine, Director
- Hohneker John, Director
- Nolet Chris, Director
- Lutzker Stuart, President of R&D
- Kung Winston, Chief Financial Officer